Approval of Daiichi Sankyo’s Vanflyta Sets Up FLT3 Head-To-Head Competition

After over a decade in development, Vanflyta scored FDA approval in newly diagnosed FLT3-ITD acute myeloid leukemia, where Novartis FLT3 inhibitor Rydapt has been on the market for years.